key: cord-0728357-byd74i6a
authors: Yonas, Emir; Alwi, Idrus; Pranata, Raymond; Huang, Ian; Lim, Michael Anthonius; Gutierrez, Eddy Jose; Yamin, Muhammad; Siswanto, Bambang Budi; Virani, Salim S.
title: Effect of heart failure on the outcome of COVID-19 — A meta analysis and systematic review
date: 2020-07-09
journal: Am J Emerg Med
DOI: 10.1016/j.ajem.2020.07.009
sha: 02e98bfe8d36c0142a472ebaa1b7307eea97838c
doc_id: 728357
cord_uid: byd74i6a

BACKGROUND: Several comorbidities have been associated with an increased risk of severity and mortality in coronavirus disease 2019 (COVID-19), including hypertension, diabetes, cerebrovascular disease, chronic kidney disease, and chronic obstructive pulmonary disease. PURPOSE: In this systematic review and meta-analysis, we attempted to investigate the association between heart failure (HF) and poor outcome in patients with COVID-19. METHODS: We performed a systematic literature search from PubMed, EuropePMC, SCOPUS, Cochrane Central Database, and medRxiv with the search terms, “Heart failure” and “COVID-19”. The outcome of interest was mortality and poor prognosis (defined by incidence of severe COVID-19 infection, admission to ICU, and use of ventilator) in patients with preexisting heart failure with coronavirus disease. RESULTS: We identified 204 potential articles from our search, and 22 duplicates were removed. After screening of the titles and abstracts of the remaining 182 articles we identified 92 potentially relevant articles. We excluded 74 studies due to the following reasons: four studies were systematic reviews, two studies were meta-analyses, three articles were literature reviews, and 65 articles did not report on the outcome of interest. Finally, we included the remaining 18 studies in our qualitative synthesis and meta-analysis. There were 21,640 patients from 18 studies. HF was associated with hospitalization in COVID19 HR was 2.37 [1.48, 3.79; p < 0.001], high heterogeneity [I(2), 82%; p < 0.001]. HF was associated with a poor outcome demonstrated by an OR of 2.86 [2.07; 3.95; p < 0.001] high heterogeneity [I(2), 80%; p < 0.001]. Patient with preexisting HF was associated with higher mortality OR of 3.46 [2.52, 4.75; p < 0.001] moderately high heterogeneity [I(2), 77%; p < 0.001]. CONCLUSION: Patients with heart failure are at increased risk for hospitalization, poor outcome, and death from COVID-19. A significant difference in mortality between patients with and without heart failure was observed, patients with heart failure having a higher mortality.

The coronavirus disease 2019 (COVID-19) has caused significant morbidity and mortality to date, with the number of new cases and deaths continue to rise at an alarming rate 1 . Although most cases of COVID-19 are asymptomatic or mild in severity, a minority of patients experience more severe symptoms of COVID-19 along with its complications, such as acute respiratory distress syndrome (ARDS), coagulopathy, multiple organ failure (MOF), and death. A number of comorbidities have been associated with an increased risk of severity and mortality in COVID-19 patients, including hypertension, diabetes, cerebrovascular disease, chronic kidney disease, and chronic obstructive pulmonary disease [2] [3] [4] [5] [6] . Individuals with preexisting cardiovascular diseases have been shown to have poor outcomes with COVID 19 7, 8 . Study from Chinese center of disease control on 72314 cases reported a case fatality rate of 10.5% for patients with preexisting cardiovascular disease, but no specific data on mortality on heart failure. 9 Due to looming possibility of poor drug compliance and other complications related to disruption in medical services, the number of patients with new or decompensated heart failure may increase. 10 Currently, the plausible mechanisms for SARS-CoV-2 (severe acute respiratory syndrome 2) to infect human cells include binding to the angiotensin-converting enzyme 2 (ACE2) receptor and inducing hyperinflammation or cytokine storm. A high expression of ACE2 receptor is commonly found in patients with heart failure 7, 8 . In this systematic review and meta-analysis, we wanted to investigate the association between heart failure with poor outcome in patients with COVID-19.

We performed a systematic search of the literature on PubMed, EuropePMC, SCOPUS, Cochrane Central Database, and medRxiv for preprint studies with the search terms, "Heart Failure" and "COVID-19". After the removal of duplicates, the abstracts were screened by two independent authors (EY and RP). Irrelevant articles were excluded. The inclusion criteria for this study were studies that studied patients with preexisting HF comorbidity with COVID-19 Infection. The outcome of interest was mortality and poor prognosis (defined by incidence of severe COVID-19 infection, admission to ICU, and use of ventilator) in patients with preexisting heart failure with coronavirus disease.This systematic search conforms to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).

Data extraction was carried out by EY, RP, MAL, and IH using a standardized form containing the following details: author name, year of publication, study design, and sample size.

This meta-analysis was conducted using Review Manager (RevMan) v5.3 (Cochrane Collaboration) software. Hazard ratio (HR) and odds ratio (OR) with 95% confidence interval (CI) were used as pooled measures for dichotomous data. Heterogeneity was assessed using Inconsistency Index (I2) ranging from 0-100%. Statistically significant heterogeneity was defined as an I 2 value above 50% or p< 0.05. The Mantel -Haenszel method was used to determine OR, and the generic inverse variance method was used to determine HR. Random effects models were implemented for analyses with significant heterogeneity. Sensitivity analyses were done to test statistical robustness of pooled results, to see whether there is significant change in pooled results by exclusion of studies, and to J o u r n a l P r e -p r o o f single out studies with high heterogeneity. Meta-analysis of prevalence were done by pooling of events of HF per total patients using the meta-analysis of proportion. Small-study effects and the risk of publication bias were assessed qualitatively using funnel plot analysis and quantitatively using regression-based Egger's test

We extracted 204 potential articles from our search, and 22 duplicates were removed. After the titles and abstracts of the remaining 182 articles were screened we obtained 92 potentially relevant articles. We excluded 74 studies due to the following reasons: four studies were systematic reviews, two studies were meta-analyses, three articles were literature reviews, and 65 articles did not report on the outcome of interest. Finally, we included the remaining 18 studies in our qualitative synthesis and meta-analysis. There were 21640 patients from 18 studies. The majority of study subjects are males ranging from 54.7% to 85%, with only two studies reported male subjects being minorities, (45 

Three studies reported a statistically significant difference in the risk of hospitalization in COVID19 patients with preexisting heart failure. 

Seven studies reported a statistically significant difference in mortality between patients with COVID-19 with and without preexisting HF. 

Three studies reported a statistically significant difference in incidence of new-onset HF in hospitalized patients with COVID- 19 (Figure 6) 

Sixteen studies were available for meta-analysis to determine the pooled prevalence of heart failure among patients with COVID-19; the meta-analysis revealed a pooled prevalence of heart failure of 9% (7-12%). (Figure 7) 

Regression-based Egger's test showed no indication of small-study effects for Heart Failure and Poor Outcome (p=0.852), Pooled HR of mortality in patients with coronavirus disease 2019 with preexisting heart failure (p=0.640), and Comparison of mortality in patients with coronavirus disease 2019 accompanied with preexisting heart failure and without heart failure (p=0.555). There was an indication of small-study effects for Risk of hospitalization in patients with preexisting heart failure (p=0.035) and Incidence of new-onset heart failure (p<0.001). The number of included studies were <10 for Risk of hospitalization in patients with preexisting heart failure, Pooled HR of mortality in patients with coronavirus disease 2019 with preexisting heart failure, and incidence new onset heart failure, thus, the results were less reliable. Analysis using funnel plot generated asymmetrical result for Heart Failure and Poor Outcome ( Figure 8A ), and Comparison of mortality in patients with coronavirus disease 2019 accompanied with preexisting heart failure and without heart failure ( Figure 8B ), with Figure 8A showing somewhat less asymmetry compared to Figure 8B . Based on Cochrane collaboration recommendation we only performed funnel plot analysis in meta-analysis involving more than 10 studies.

In this meta-analysis, we observed an association between HF and poor outcome in patients with COVID-19, a higher risk of death and hospitalization in those with preexisting HF, and higher mortality in those with preexisting HF compared to patients without HF.

As with other types of pneumonia, preexisting cardiovascular diseases, including HF, are risk factors for poor prognosis during and after the course of pneumonia. 11 The effect of an infective organism on the myocardium can cause non-ischemic cardiac injury. The systemic inflammatory response, which is particularly excessively elevated in COVID-19, can also result in kidney injury and impair sodium and water metabolism, which may precipitate the worsening of HF. 12 Recent studies on the role of ACE2 in COVID-19 infection have reported that ACE2 levels are 50% higher in male patients with HF. [13] [14] [15] This finding explains the higher risk of poor prognosis, hospitalization, and death in this population in the event of occurrence of COVID-19. In this metaanalysis, the majority of the studies had higher number of male patients than female patients.

In patients with coexisting HF and diabetes, who are in a pro-inflammatory state, the membranebound ACE2 protein can be cleaved by ADAM17, resulting in the release of ACE2 into the interstitium and blood circulation. 16 This inflammatory response, which occurs in COVID-19 as an elevated immune response 17, 18 might also explain the increase in mortality in patients with COVID-19 accompanied with HF. The excessive inflammatory response and oxidative stress in these patients predispose them to a more severe clinical course of COVID-19. 19 This phenomenon is particularly significant in patients with preexisting HF since these patients suffer from decreased circulatory and physiological reserves. Older patients with HF commonly suffer from multiple comorbidities, deterioration in function of multiple organ systems, and functional decline. 20,21 ACE2 is an enzyme involved in the RAAS pathway; however, it differs from ACE in not being capable of converting angiotensin I into angiotensin II. Furthermore, as opposed to the vasoconstrictor property of angiotensin type 1 receptors, ACE2 via the ACE-2 receptors cleaves angiotensin II into angiotensin 1-7, which has vasodilatory properties. 22 Based on these explanations, it is easy for us to conclude regarding the dangers of upregulation of ACE2 as in patients being treated with renin-angiotensin system blockers (RASB). One study has even proposed ceasing administration of RASB in patients with COVID-19 on these drugs. 23 However, this does not seem to be the case, and several other authors have questioned this hypothesis. [24] [25] [26] [27] The rationale for this rebuttal is based upon several in vitro studies, which revealed that upon entry into alveolar cells using membrane-bound ACE-2 receptors, SARS-CoV-2 downregulates the expression and causes internalization of ACE2 receptors. The result of this process is a decrease in angiotensin-II to angiotensin (1-7) conversion and an increase in the availability of angiotensin II to bind to the AT1 receptor. This induces cellular inflammation, oxidative stress, vasoconstriction, fibrosis, and aldosterone activation, which may eventually lead to lung injury. [28] [29] [30] [31] [32] The use of RASB may serve as a protective measure against lung injury by the inhibition of angiotensin II synthesis using ACEIs and blockade of AT1R by ARBs. This would result in a skew of the RAAS towards angiotensin (1-7) and its subsequent interaction with Mas-receptors, which may minimize the risk of lung injury. 29, 33 The result of this meta-analysis is similar to that of previous studies in which patients with preexisting heart HF demonstrated an elevated risk of poor outcome, hospitalization, and death [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] . 34 35-41 42-50 51,52 Compared to other diseases, based on our pooled results, patients with HF suffering from SARS-CoV-2 infection have a threefold increased risk of in-hospital mortality compared to patients with HF who develop influenza, OR 3.46 [2.52, 4. Studies have shown a poorer prognosis in patients with HF who develop influenza. 53, 54 As a result of the decreased physiological reserve, influenza virus infection in patients with HF is associated with a severe course and significant hemodynamic compromise, which often requires cardiac support. 56 Influenza vaccination in these patients is associated with a reduced risk of all-cause and cardiovascular death, furthermore receiving >1 influenza vaccine is associated with 18% reduction in both all-cause and cardiovascular death (all-cause death: 0.82; 95% CI,0.81-0.84; P<0.001; cardiovascular death: 0.82; 95% CI, 0.81-0.84; P<0.001), in the event of influenza infection, patients with heart failure may fail to cope with the increased metabolic demand which is caused by the infection itself, as a result, decompensation or exacerbation in heart failure symptoms may occur. 57 J o u r n a l P r e -p r o o f Patients with HF are currently classified as a high-priority group to be vaccinated with the influenza vaccine. 58 Based on these findings, once an effective vaccine for SARS-CoV-2 infection becomes available, patients with HF should be prioritized to be vaccinated even in case of COVID-19.

We observed some limitations of this meta-analysis, such as the use of preprint studies included in this meta-analysis. Additionally, several studies have been conducted in the same cities/regions, posing a risk of subject overlap. Data regarding the difference between new-onset and worsening of HF in patients in the studies was rarely available. Data regarding staging of HF was also rarely found. Additionally, in patients with HF suffering from a severe course of COVID-19 infection, data regarding the use of vasopressors and inotropic agents as well as the incidence of cardiogenic shock was lacking.

In conclusion, patients with HF are at increased risk for poor outcomes such as hospitalization, and death from COVID-19. A significant difference in mortality between patients with and without HF was observed, those with HF showing higher mortality rates. These findings probably stem from the reduced physiological reserves in patients with HF. Mortality of patients with HF accompanied with SARS-CoV-2 infection is higher than that of patients with influenza, but lower than that of patients with MERS-CoV. Thus, if SARS-CoV-2 vaccine becomes available, patients with HF should be prioritized to be vaccinated.

J o u r n a l P r e -p r o o f Journal Pre-proof J o u r n a l P r e -p r o o f 

World Health Organization. Coronavirus Disease 2019 (COVID-19) Situation Report -95

Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression

Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia -A systematic review, meta-analysis, and metaregression

Effect of chronic obstructive pulmonary disease and smoking on the outcome of COVID-19

Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis

Elevated N-terminal pro-brain natriuretic peptide is J o u r n a l P r e -p r o o f associated with increased mortality in patients with COVID-19: systematic review and metaanalysis

Impact of Cerebrovascular and Cardiovascular Diseases on Mortality and Severity of COVID-19 -Systematic Review, Metaanalysis, and Meta-regression

Potential role of telemedicine in solving ST-segment elevation dilemmas in remote areas during the COVID-19 pandemic

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

A wave of non-communicable diseases following the COVID-19 pandemic

Community-Acquired Pneumonia Requiring Admission to an Intensive Care Unit. Medicine (Baltimore)

Acute pneumonia and the cardiovascular system

New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) II: Albumin Suppresses Angiotensin Converting Enzyme (ACE) Activity in Human. Karamyan V

New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) IV: Circulating ACE2 as a Biomarker of Systolic Dysfunction in Human Hypertension and Heart Failure. Karamyan V

Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province

Dynamics of ADAM17-Mediated Shedding of ACE2 Applied to Pancreatic Islets of Male db/db Mice

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe

The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease

<scp>COVID</scp> 19 and heart failure: from infection to inflammation and angiotensin <scp>II</scp> stimulation. Searching for evidence from a new disease

Frailty in Heart Failure: Implications for Management

Multiorgan Failure With Emphasis on Acute Kidney Injury and Severity of COVID-19: Systematic Review and Meta-Analysis

Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

Antihypertensive drugs and risk of COVID-19?

Antihypertensive drugs and risk of COVID-19?

Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers

Antihypertensive drugs and risk of COVID-19?

Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers

Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19

Replication-dependent downregulation of cellular angiotensin-converting enzyme 2 protein expression by human coronavirus NL63

The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis

C-reactive protein, procalcitonin, Ddimer, and ferritin in severe coronavirus disease-2019: a meta-analysis

Letter in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers

Management of Heart Failure Patients with <scp>COVID</scp> -19. A Joint Position Paper of the Chinese Heart Failure Association &amp

National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology

Characterization and clinical course of 1000 Patients with COVID-19 in New York: retrospective case series

COVID-19 management in a UK NHS Foundation Trust with a High Consequence Infectious Diseases centre: a detailed descriptive analysis

COVID-19 Infections and Outcomes in a Live Registry of Heart Failure Patients Across an Integrated Health Care System

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

Pre-Existing Traits Associated with Covid-19 Illness Severity

Patient trajectories and risk factors for severe outcomes among persons hospitalized for COVID-19 in the Maryland/DC region

Cardiac Structural and Functional Characteristics in Patients with Coronavirus Disease 2019: A Serial Echocardiographic Study

Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy

Effect of underlying comorbidities on the infection and severity of COVID-19 in South Korea

Critical Care for Severe COVID-19: A Population-based Study from a Province with Low Case-fatality Rate in China

Clinical Characteristics of Hospitalized Covid-19 Patients

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study

Characteristics and predictors of hospitalization and death in the first 9,519 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: A nationwide cohort

Characteristics and outcomes of a cohort of SARS-CoV-2 patients in the Province of Reggio Emilia

What factors increase the risk of complications in SARS-CoV-2 positive patients? A cohort study in a nationwide Israeli health organization

Critically Ill Patients with COVID-19 in China: A Multicenter Retrospective Observational Study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Effect of Influenza on Outcomes in Patients With Heart Failure

Relation of Concomitant Heart Failure to Outcomes in Patients Hospitalized With Influenza

Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study

The hidden burden of influenza: A review of the extra-pulmonary complications of influenza infection. Influenza Other Respi Viruses

Influenza Vaccine in Heart Failure

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices -United States, 2019-20 Influenza Season

Emir Yonas: Conceptualization, Formal Analysis, Methodology, Writing -Original Draft

Idrus Alwi : Writing -Review & Editing Raymond Pranata : Writing -Review & Editing, Formal Analysis, Methodology Ian Huang : Writing -Review & Editing Michael Anthonius Lim: Writing -Review & editing

Writing -Review & Editing Muhammad Yamin : Writing -Review & Editing Bambang Budi Siswanto : Writing -Review & Editing Salim S Virani : Conceptualization, Writing -Review & Editing

None Funding:

The authors of this manuscript has no conflict of interest